Criteria for selecting suitable infectious diseases for phage therapy

Viruses

Volumn 10, Issue 4, 2018, Pages

  Harper, David R ^a  

^a Evolution Biotechnologies   (United Kingdom)

Author keywords

Bacterial disease; Bacteriophage; Infection; Phage therapy; Target selection; Therapy

Indexed keywords

MONOCLONAL ANTIBODY; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIOPHAGE; BIOLOGICAL CONTROL AGENT; CROSS RESISTANCE; DRUG QUALITY; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; GEOGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MARKET; NONHUMAN; PATENT; PHAGE THERAPY; REVIEW; STUDY DESIGN; TREATMENT OUTCOME; ANIMAL; BACTERIUM; CLINICAL TRIAL (TOPIC); COMMUNICABLE DISEASE; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; MICROBIOLOGY; PHYSIOLOGY; PRECLINICAL STUDY; VIROLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BACTERIOPHAGES; CLINICAL TRIALS AS TOPIC; COMMUNICABLE DISEASES; DRUG ADMINISTRATION ROUTES; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, BACTERIAL; HUMANS; PHAGE THERAPY;

EID: 85045089821     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v10040177     Document Type: Review

References (55)

1. D’Herelle, F. Sur le role du microbe bacteriophage dans la typhose aviare. Comptes Rendus de l’Académie des Sciences Paris 1919, 169, 932–934.
2. Eaton, M.D.; Bayne-Jones, S. Bacteriophage therapy: Review of the principles and results of the use of bacteriophage in the treatment of infections. JAMA 1934, 103, 1769–1776, 1847–1853, 1934–1939. [CrossRef]
3. Krueger, A.P.; Scribner, E.J. The bacteriophage: Its nature and its therapeutic use. JAMA 1941, 116, 2160–2167. [CrossRef]
4. Chan, M. WHO Director-General briefs UN on Antimicrobial Resistance. 2016. Available online: http://www.who.int/dg/speeches/2016/antimicrobial-resistance-un/en/(accessed on 9 March 2018).
5. Harper, D.R.; Burrowes, B.H.; Kutter, E.M.Bacteriophage: Therapeutic Uses. In Encyclopedia of Life Sciences; John Wiley and Sons: Chichester, UK, 2014.
6. Harper, D.; Abedon, S.; Burrowes, B.; McConville, M. (Eds.) Bacteriophgages: Biology, Technology, Therapy; Springer: Cham, Switzerland, 2018; ISBN 978-3-319-40598-8. Available online: https://link.springer.com/referencework/10.1007/978-3-319-40598-8#about (accessed on 9 March 2018).
7. Czaplewski, L.; Bax, R.; Clokie, M.; Dawson, M.; Fairhead, H.; Fischetti, V.A.; Foster, S.; Gilmore, B.F.; Hancock, R.E.; Harper, D.; et al. Alternatives to antibiotics—A pipeline portfolio review. Lancet Infect. Dis. 2016, 16, 239–251. [CrossRef]
8. Hagens, S.; Habel, A.; Bläsi, U. Augmentation of the Antimicrobial Efficacy of Antibiotics by Filamentous Phage. Microb. Drug Resist. 2006, 12, 164–168. [CrossRef] [PubMed]
9. Chan, B.K.; Sistrom, M.; Wertz, J.E.; Kortright, K.E.; Narayan, D.; Turner, P.E. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci. Rep. 2016, 6, 26717. [CrossRef] [PubMed]
10. Lu, T.K.; Collins, J.J. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. PNAS 2009, 106, 4629–4634. [CrossRef] [PubMed]
11. Wright, A.; Hawkins, C.; Änggård, E.; Harper, D.A. Controlled clinical trial of a therapeutic bacteriophage in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; A preliminary report of efficacy. Clin. Otolaryngol. 2009, 34, 349–357. [CrossRef] [PubMed]
12. Blackwell, A. The Potential for Bacteriophage to Control Soft Rot Development in Store. Available online: https://potatoes.ahdb.org.uk/sites/default/files/publication_upload/APS%20Biocontrol%20Ltd. pdfDevelopmentDevelopment(accessed on 9 March 2018).
13. Ceri, H.; Olson, M.E.; Stremick, C.; Read, R.R.; Morck, D.; Buret, A. The Calgary biofilm device: New technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J. Clin. Microbiol. 1999, 37, 1771–1776. [PubMed]
14. Harper, D.R.; Parracho, H.M.; Walker, J.; Sharp, R.; Hughes, G.; Werthén, M.; Lehman, S.; Morales, S. Bacteriophages and biofilms. Antibiotics 2014, 3, 270–284. [CrossRef]
15. Kumar, S.R.; Markusic, D.M.; Biswas, M.; High, K.A.; Herzog, R.W. Clinical development of gene therapy: Results and lessons from recent successes. Mol. Ther. Methods Clin. Dev. 2016, 3, 16034. [CrossRef] [PubMed]
16. FiercePharma. With Its Launch Fizzling Out, UniQure Gives Up on $1M+ Gene Therapy Glybera. Available online: https://www.fiercepharma.com/pharma/uniqure-gives-up-1m-gene-therapy-glybera (accessed on 9 March 2018).
17. Brockhurst, M.A.; Koskella, B.; Zhang, Q.G. Bacteria-Phage Antagonistic Coevolution and the Implications for Phage Therapy. In Bacteriophages: Biology, Technology, Therapy; Harper, D., Abedon, S., Burrowes, B., McConville, M., Eds.; Springer Nature: Cham, Switzerland, 2017.
18. Sillankorva, S.M.; Oliveira, H.; Azeredo, J. Bacteriophages and Their Role in Food Safety. Int. J. Microbiol., 2012, 2012, 863945. [CrossRef] [PubMed]
19. Sarker, S.A.; Sultana, S.; Reuteler, G.; Moine, D.; Descombes, P.; Charton, F.; Bourdin, G.; McCallin, S.; Ngom-Bru, C.; Neville, T.; et al. Oral Phage Therapy of Acute Bacterial Diarrhea with Two Coliphage Preparations: A Randomized Trial in Children From Bangladesh. EBioMedicine 2016, 4, 124–137. [CrossRef] [PubMed]
20. Soothill, J.S. Treatment of experimental infections of mice with bacteriophages. J. Med. Microbiol. 1992, 37, 258–261. [CrossRef] [PubMed]
21. Watanabe, R.; Matsumoto, T.; Sano, G.; Ishii, Y.; Tateda, K.; Sumiyama, Y.; Uchiyama, J.; Sakurai, S.; Matsuzaki, S.; Imai, S. Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob. Agents Chemother. 2007, 51, 446–452. [CrossRef] [PubMed]
22. Hawkins, C.; Harper, D.; Burch, D.; Änggård, E.; Soothill, J. Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: A before/after clinical trial. Vet. Microbiol. 2010, 146, 309–313. [CrossRef] [PubMed]
23. Marza, J.A.; Soothill, J.S.; Boydell, P.; Collyns, T.A. Multiplication of therapeutically administered bacteriophages in Pseudomonas aeruginosa infected patients. Burns 2006, 32, 644–646. [CrossRef] [PubMed]
24. Phagoburn. Available online: http://www.phagoburn.eu/(accessed on 9 March 2018).
25. Rhoads, D.D.; Wolcott, R.D.; Kuskowski, M.A.; Wolcott, B.M.; Ward, L.S.; Sulakvelidze, A. Bacteriophage therapy of venous leg ulcers in humans: Results of a phase I safety trial. J. Wound Care 2009, 18, 237–243. [CrossRef] [PubMed]
26. Rose, T.; Verbeken, G.; De Vos, D.; Merabishvili, M.; Vaneechoutte, M.; Lavigne, R.; Jennes, S.; Zizi, M.; Pirnay, J.P. Experimental phage therapy of burn wound infection: Difficult first steps. Int. J. Burns Trauma 2014, 4, 66–73. [PubMed]
27. Cole, S.T.; Eisenach, K.D.; McMurray, D.N.; Jacobs, W.R.(Eds.) Tuberculosis and the Tubercle Bacillus; ASM Press: Washington, DC, USA, 2005; ISBN 1-55581-295-3.
28. PubMed Health. Closed Comedones. Available online: https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0025363/(accessed on 9 March 2018).
29. Payne, R.J.H.; Vincent, A.A. Evidence for a Phage Proliferation Threshold? J. Virol. 2002, 76, 13123–13124. [CrossRef] [PubMed]
30. Vinner, G.K.; Vladisavljević, G.T.; Clokie, M.R.J.; Malik, D.J. Microencapsulation of Clostridium difficile specific bacteriophages using microfluidic glass capillary devices for colon delivery using pH triggered release. PLoS ONE 2017, 12, e0186239. [CrossRef] [PubMed]
31. Chibani-Chennoufi, S.; Sidoti, J.; Bruttin, A.; Kutter, E.; Sarker, S.; Brüssow, H. In vitro and in vivo bacteriolytic activities of Escherichia coli phages: Implications for phage therapy. Antimicrob. Agents Chemother. 2004, 48, 2558–2569. [CrossRef] [PubMed]
32. Ryan, E.M.; Gorman, S.P.; Donnelly, R.F.; Gilmore, B.F. Recent advances in bacteriophage therapy: How delivery routes, formulation, concentration and timing influence the success of phage therapy. J. Pharm. Pharmacol. 2011, 63, 1253–1264. [CrossRef] [PubMed]
33. Jończyk-Matysiak, E.; Weber-Dabrowska, B.; Owczarek, B.; Międzybrodzki, R.; Łusiak-Szelachowska, M.; Łodej, N.; Górski, A. Phage-Phagocyte Interactions and Their Implications for Phage Application as Therapeutics. Viruses 2017, 9, 150. [CrossRef] [PubMed]
34. Łusiak-Szelachowska, M.; Żaczek, M.; Weber-Dabrowska, B.; Międzybrodzki, R.M.; Letkiewicz, S.; Fortuna, W.; Rogóż, P.; Szufnarowski, K.; Jończyk-Matysiak, E.; Olchawa, E.; et al. Antiphage activity of sera during phage therapy in relation to its outcome. Future Microbiol. 2017, 12, 109–117.
35. Ledford, H. Myriad ruling causes confusion. Nature 2013, 498, 281–282. [CrossRef] [PubMed]
36. Schooley, R.T.; Biswas, B.; Gill, J.J.; Hernandez-Morales, A.; Lancaster, J.; Lessor, L.; Barr, J.J.; Reed, S.L.; Rohwer, F.; Benler, S.; et al. Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails to Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection. Antimicrob. Agents Chemother. 2017, 61, e00954-17. [CrossRef] [PubMed]
37. Dalmasso, M.; de Haas, E.; Neve, H. Isolation of a Novel Phage with Activity against Streptococcus mutans Biofilms. PLoS ONE 2015, 10, e0138651. [CrossRef] [PubMed]
38. Abedon, S.T.; Thomas-Abedon, C. Phage therapy pharmacology. Curr. Pharm. Biotechnol. 2010, 11, 28–47. [CrossRef] [PubMed]
39. Pirnay, J.P.; De Vos, D.; Verbeken, G.; Merabishvili, M.; Chanishvili, N.; Vaneechoutte, M.; Zizi, M.; Laire, G.; Lavigne, R.; Huys, I.; et al. The phage therapy paradigm: Prêt-à-porter or sur-mesure? Pharm. Res. 2011, 28, 934–937. [CrossRef] [PubMed]
40. Feiner, R.; Argov, T.; Rabinovich, L.; Sigal, N.; Borovok, I.; Herskovits, A.A. A new perspective on lysogeny: Prophages as active regulatory switches of bacteria. Nat. Rev. Microbiol. 2015, 13, 641–650. [CrossRef] [PubMed]
41. Hyman, P.; Abedon, S.T. Bacteriophage host range and bacterial resistance. Adv. Appl. Microbiol. 2010, 70, 217–248. [PubMed]
42. Nale, J.Y.; Spencer, J.; Hargreaves, K.R.; Buckley, A.M.; Trzepiński, P.; Douce, G.R.; Clokie, M.R. Bacteriophage Combinations Significantly Reduce Clostridium difficile Growth in Vitro and Proliferation in Vivo. Antimicrob. Agents Chemother. 2015, 60, 968–981. [CrossRef] [PubMed]
43. Hargreaves, K.R.; Clokie, M.R. Clostridium difficile phages: Still difficult? Front. Microbiol. 2014, 28, 184. [CrossRef] [PubMed]
44. Colavecchio, A.; Cadieux, B.; Lo, A.; Goodridge, L.D. Bacteriophages Contribute to the Spread of Antibiotic Resistance Genes among Foodborne Pathogens of the Enterobacteriaceae Family—A Review. Front. Microbiol. 2017, 20, 1108. [CrossRef] [PubMed]
45. Strauch, E.; Lurz, R.; Beutin, L. Characterization of a Shiga toxin-encoding temperate bacteriophage of Shigella sonnei. Infect. Immun. 2001, 69, 7588–7595. [CrossRef] [PubMed]
46. Christie, G.E.; Dokland, T. Pirates of the Caudovirales. Virology 2012, 434, 210–221. [CrossRef] [PubMed]
47. Ackermann, H.-W.; Tremblay, D.; Moineau, S. Long-term bacteriophage preservation. W.F.C.C. Newsl. 2004, 38, 35–40.
48. European Pharmacopoeia Online. Available online: http://online.edqm.eu/EN/entry.htm (accessed on 9 March 2018).
49. USP-NF. Available online: http://www.uspnf.com/?_ga=2.80419031.1739394632.1520820978-1625466886. 1520820978 (accessed on 9 March 2018).
50. Verbeken, G.; Pirnay, J.P.; De Vos, D.; Jennes, S.; Zizi, M.; Lavigne, R.; Casteels, M.; Huys, I. Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine. Arch. Immunol. Ther. Exp. (Warsz.) 2012, 60, 161–172. [CrossRef] [PubMed]
51. Verbeken, G.; Pirnay, J.P.; Lavigne, R.; Jennes, S.; De Vos, D.; Casteels, M.; Huys, I. Call for a dedicated European legal framework for bacteriophage therapy. Arch. Immunol. Ther. Exp. (Warsz.) 2014, 62, 117–129. [CrossRef] [PubMed]
52. Huys, I.; Pirnay, J.P.; Lavigne, R.; Jennes, S.; De Vos, D.; Casteels, M.; Verbeken, G. Paving a regulatory pathway for phage therapy. Europe should muster the resources to financially, technically and legally support the introduction of phage therapy. EMBO Rep. 2013, 14, 951–954. [CrossRef] [PubMed]
53. Defoirdt, T. Quorum-Sensing Systems as Targets for Antivirulence Therapy. Trends Microbiol. 2017, 26, 313–328. [CrossRef] [PubMed]
54. Harper, D.R.; Enright, M.C. Bacteriophages for the treatment of Pseudomonas aeruginosa infections. J. Appl. Microbiol. 2010, 111, 1–7. [CrossRef] [PubMed]
55. Soothill, J.S.; Hawkins, C.; Anggard, E.A.; Harper, D.R. Therapeutic use of bacteriophages (letter). Lancet Infect. Dis. 2004, 4, 544–545. [CrossRef]